论文部分内容阅读
最近于葡萄牙首都里斯本召开的国际骨质疏松(OP)大会上 ,Servier公司新研制的抗OP药Protos(strontiamranelate)表明具有双重治疗作用而无目前一些抗OP药常见的胃肠道副作用。这一信息来源于在该会上首次报道的一项为期5年的Ⅲ期临床试验S
At the recent International Osteoporosis Conference held in Lisbon, Portugal, Servier’s newly developed strontiamrane anti-OP drug showed a dual therapeutic effect without the gastrointestinal side effects commonly seen with some anti-OP drugs. This information comes from the first report in the meeting of a 5-year phase Ⅲ clinical trial S